MBX Biosciences (MBX) Minority Interest (2023 - 2024)

MBX Biosciences (MBX) reported Minority Interest of $115.9 million for Q2 2024, up 217.41% sequentially from $36.5 million in Q1 2024.

MBX Biosciences (MBX) Minority Interest (2023 - 2024) Analysis & Trends

MBX Biosciences (MBX) has 2 years of Minority Interest data on file, last reported at $115.9 million in Q2 2024.

For the quarter ending Q2 2024, Minority Interest changed N/A year-over-year to $115.9 million; the trailing twelve-month figure through Jun 2024 stood at $115.9 million (changed N/A YoY), and the FY2023 full-year result was $36.5 million, changed N/A from the prior year.
Minority Interest climbed to $115.9 million in Q2 2024, from $36.5 million in the prior quarter.
In the past five years, Minority Interest ranged from a high of $115.9 million in Q2 2024 to a low of $36.5 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	MBX Biosciences	2.96 Bn	2.96 Bn	-

Download Data